CalciMedica Appoints Dr. Jonathan Lim to Board

Ticker: CALC · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1534133

Calcimedica, INC. 8-K Filing Summary
FieldDetail
CompanyCalcimedica, INC. (CALC)
Form Type8-K
Filed DateJan 14, 2025
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0, $40,000
Sentimentneutral

Sentiment: neutral

Topics: board-appointment, management-change

TL;DR

CalciMedica adds Dr. Jonathan Lim to its board, bringing biotech leadership experience.

AI Summary

On January 10, 2025, CalciMedica, Inc. announced the election of Dr. Jonathan Lim to its Board of Directors. Dr. Lim, a seasoned executive with experience in the life sciences industry, will serve as a Class II director. His appointment is effective immediately and aims to leverage his expertise in strategic growth and development for the company.

Why It Matters

The addition of an experienced director like Dr. Lim could signal a strategic shift or focus on growth for CalciMedica, potentially impacting its future development and market position.

Risk Assessment

Risk Level: low — The filing reports a routine board appointment, which typically carries low inherent risk.

Key Players & Entities

FAQ

What is the effective date of Dr. Jonathan Lim's election to the Board of Directors?

Dr. Jonathan Lim's election to the Board of Directors is effective immediately as of January 10, 2025.

What class of director will Dr. Jonathan Lim serve as?

Dr. Jonathan Lim will serve as a Class II director.

What is CalciMedica, Inc.'s primary business?

CalciMedica, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.

Where is CalciMedica, Inc. headquartered?

CalciMedica, Inc. is located at 505 Coast Boulevard South, Suite 307, La Jolla, CA 92037.

What is the filing date of this 8-K report?

This 8-K report was filed on January 14, 2025.

Filing Stats: 648 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2025-01-14 07:05:46

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CALCIMEDICA, INC. Date: January 14, 2025 By: /s/ A. Rachel Leheny A. Rachel Leheny, Ph.D. Chief Executive Officer ( Principal Executive Officer )

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing